Fresenius SE & Co. (OTCMKTS:FSNUY) Sees Strong Trading Volume – Here’s What Happened

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) shares saw an uptick in trading volume on Friday. Approximately 1,327,216 shares traded hands during mid-day trading, an increase of 799% from the previous session’s volume of 147,664 shares. The stock last traded at $12.4170 and had previously closed at $12.45.

Wall Street Analyst Weigh In

Several analysts have commented on FSNUY shares. Morgan Stanley restated an “overweight” rating on shares of Fresenius SE & Co. in a report on Tuesday, July 21st. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of Fresenius SE & Co. in a report on Thursday, August 6th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy”.

Get Fresenius SE & Co. alerts:

Check Out Our Latest Analysis on Fresenius SE & Co.

Fresenius SE & Co. Trading Down 0.0%

The stock has a market cap of $28.04 billion, a price-to-earnings ratio of 15.75 and a beta of 0.60. The business has a 50-day simple moving average of $13.18 and a two-hundred day simple moving average of $12.40. The company has a debt-to-equity ratio of 0.41, a quick ratio of 0.97 and a current ratio of 1.28.

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Fresenius SE & Co. had a return on equity of 10.25% and a net margin of 6.67%.The business had revenue of $6.91 billion during the quarter, compared to the consensus estimate of $6.65 billion. As a group, research analysts forecast that Fresenius SE & Co. will post 1.08 EPS for the current year.

Fresenius SE & Co. Company Profile

(Get Free Report)

Fresenius SE & Co KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network.

Featured Articles

• Five stocks we like better than Fresenius SE & Co.
• AST SpaceMobile’s BlueBird Progress Comes With Several Risks Still Unresolved
• Time to Nibble on MCD Stock After it Enters Oversold Territory?
• McCormick Stock Trades Cheap, Offers Dividend Growth and Unilever Deal Upside
• Corning and AT&T’s $3 Billion Fiber Deal Reveals Where AI Spending Goes Next

Receive News & Ratings for Fresenius SE & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. and related companies with MarketBeat.com's FREE daily email newsletter.